MEDIPOST enters multi-year exclusive licensing deal with Teikoku Seiyaku for CARTISTEM® commercialization in Japan SEOUL — MEDIPOST Co., Ltd., a leading South Korean regenerative medicine company, has announced a strategic multi-year licensing partnership with Japan-based Teikoku Seiyaku Co., Ltd., granting exclusive commercialization rights for its cartilage repair therapy CARTISTEM® in Japan. The agreement strengthens MEDIPOST’s footprint in one of the world’s most advanced medical markets while addressing Japan’s significant […]

MEDIPOST enters multi-year exclusive licensing deal with Teikoku Seiyaku for CARTISTEM® commercialization in Japan #RegenerativeMedicine #HealthcareInnovation #JapanHealthcare #Partnership #CARTISTEM

MEDIPOST Partners with Teikoku Seiyaku for Revolutionary Osteoarthritis Treatment in Japan MEDIPOST has announced a strategic partnership with Teikoku Seiyaku to bring CARTISTEM®, a groundbreaking treatment for knee osteoarthritis, to Japan. This collaboration is set to enhance the availability of innovative therapies for patients in need.

MEDIPOST Partners with Teikoku Seiyaku for Revolutionary Osteoarthritis Treatment in Japan #South_Korea #Seoul #CARTISTEM #MEDIPOST #Teikoku_Seiyaku